Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

EPT-17 Phase I Study of BRAF Inhibitor (Vemurafenib) in combination with the mTOR inhibitor (Everolimus) in BRAFV600E positive childhood and AYA brain tumors Neuro-Oncology 2016;18(suppl 3):iii27.

Date

08/06/2019

Author List

Tanaka R, Khatua S, Zaky W, Penas-Prado M, Weathers S-P, Subbiah V.

Author

Ryuma Tanaka MD Assistant Professor in the Pediatrics department at Medical College of Wisconsin